Global biopharmaceutical company UCB is presenting 24 abstracts from its neurology portfolio at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego from April 5-9. The research covers rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome, generalized myasthenia gravis, and thymidine kinase 2 deficiency. These presentations underscore UCB’s commitment to advancing neurological research and improving patient outcomes.